Back to dashboard
CommercialCoverageMedium impact

08.01.62f, Nivolumab (Opdivo®), Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™)

Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

This is a policy update for Nivolumab (Opdivo®) and Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™) that became effective July 1, 2025. The policy affects commercial insurance coverage for these oncology medications, but specific details require accessing the full policy document.

Action Required

Action needed
By July 1, 2025: Billing team should review the full policy at the provided URL to understand specific coverage changes for Nivolumab (Opdivo) and Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig). Update prior authorization requirements and billing procedures as specified in the complete policy document.

Related policy hubs